PT1399186E - Medicamento para o tratamento de tumores e das suas metástases por utilização de uma molécula de ligação contra a sialoproteína óssea - Google Patents

Medicamento para o tratamento de tumores e das suas metástases por utilização de uma molécula de ligação contra a sialoproteína óssea Download PDF

Info

Publication number
PT1399186E
PT1399186E PT02748771T PT02748771T PT1399186E PT 1399186 E PT1399186 E PT 1399186E PT 02748771 T PT02748771 T PT 02748771T PT 02748771 T PT02748771 T PT 02748771T PT 1399186 E PT1399186 E PT 1399186E
Authority
PT
Portugal
Prior art keywords
bsp
bone
antibodies
active substance
tumor
Prior art date
Application number
PT02748771T
Other languages
English (en)
Portuguese (pt)
Inventor
Franz Paul Armbruster
Markus Karmatschek
Werner Franz Nader
Ulf Joerg Forsmann
Mats Paulsson
Martin R Berger
Original Assignee
Armbruster Biotechnology Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Armbruster Biotechnology Gmbh filed Critical Armbruster Biotechnology Gmbh
Publication of PT1399186E publication Critical patent/PT1399186E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PT02748771T 2001-06-13 2002-06-12 Medicamento para o tratamento de tumores e das suas metástases por utilização de uma molécula de ligação contra a sialoproteína óssea PT1399186E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01114388 2001-06-13
DE10128639 2001-06-15

Publications (1)

Publication Number Publication Date
PT1399186E true PT1399186E (pt) 2010-02-23

Family

ID=26009516

Family Applications (1)

Application Number Title Priority Date Filing Date
PT02748771T PT1399186E (pt) 2001-06-13 2002-06-12 Medicamento para o tratamento de tumores e das suas metástases por utilização de uma molécula de ligação contra a sialoproteína óssea

Country Status (10)

Country Link
US (2) US7825219B2 (enExample)
EP (1) EP1399186B1 (enExample)
JP (1) JP4570355B2 (enExample)
AT (1) ATE448796T1 (enExample)
AU (1) AU2002319223A1 (enExample)
DE (1) DE50214008D1 (enExample)
DK (1) DK1399186T3 (enExample)
ES (1) ES2336770T3 (enExample)
PT (1) PT1399186E (enExample)
WO (1) WO2002100899A2 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1514929A1 (en) * 2003-09-12 2005-03-16 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Antisense oligonucleotides for prevention of metastasis formation of cancer cells
EP1888631B1 (de) * 2005-05-31 2009-09-23 Ralf Jochem Therapeutsche zusammensetzung zur vorbeugung und bekämpfung von knochenmetastasen
US20080219996A1 (en) * 2005-09-26 2008-09-11 Thea Kalebic Molecular Markers Associated with Bone Metastasis
CA2735020A1 (en) * 2008-08-29 2010-03-04 Symphogen A/S Method for cloning avian-derived antibodies
CA2958263C (en) 2014-08-19 2022-12-13 Immundiagnostik Ag Medicament and apparatus for treating chronic kidney disease
CN117999093A (zh) * 2021-07-20 2024-05-07 威廉马歇莱思大学 用于骨靶向治疗的经改造组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4853219A (en) * 1987-08-06 1989-08-01 President And Fellows Of Harvard College Antibodies to angiogenin: immunotherapeutic agents
US5601819A (en) * 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5340934A (en) * 1989-11-03 1994-08-23 The United States Of Americas As Represented By The Secretary Of Health & Human Services CDNA sequences of human bone matrix proteins
EP0590058B1 (en) * 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
DE60025342D1 (de) 1999-04-09 2006-03-30 Us Gov Health & Human Serv Komplex aus n-glykolisierten proteinen (siblings) und faktor h

Also Published As

Publication number Publication date
WO2002100899A3 (de) 2003-12-18
US7825219B2 (en) 2010-11-02
EP1399186A2 (de) 2004-03-24
US20050069547A1 (en) 2005-03-31
JP4570355B2 (ja) 2010-10-27
DK1399186T3 (da) 2010-03-29
ATE448796T1 (de) 2009-12-15
JP2005506959A (ja) 2005-03-10
ES2336770T3 (es) 2010-04-16
US8808691B2 (en) 2014-08-19
US20110091379A1 (en) 2011-04-21
AU2002319223A1 (en) 2002-12-23
WO2002100899A2 (de) 2002-12-19
EP1399186B1 (de) 2009-11-18
DE50214008D1 (de) 2009-12-31

Similar Documents

Publication Publication Date Title
ES2646168T3 (es) Anticuerpos monoclonales para el receptor del factor de crecimiento de fibroblastos 2
US8987205B2 (en) Polynucleotides encoding recombinant lubricin molecules and uses thereof
ES2264929T3 (es) Acidos nucleicos y polipeptidos del factor 19 de crecimiento fibroblastico (fgf-19) y procedimientos de utilizacion para el tratamiento de la obesidad.
EA025891B1 (ru) ВАРИАНТЫ, ПРОИСХОДЯЩИЕ ИЗ ActRIIB, И ИХ ПРИМЕНЕНИЕ
JPH09510605A (ja) Ｅｇｆレセプターに対する抗体及びその抗腫瘍効果
JP2012520661A (ja) 抗血管新生融合タンパク質
BR9709350B1 (pt) anticorpo recombinante ou fragmento de anticorpo recombinante, composiÇço farmacÊutica, Ácido nuclÈico, bacteriàfago, cÉlula hospedeira bacteriana ou de levedura, uso de anticorpo ou fragmento de anticorpo recombinante, processo para a produÇço do mesmo, e, kit diagnàstico.
US8808691B2 (en) Method for treating tumors and their metastases
ES2325485T3 (es) Metodos para identificar compuestos para regular la masa o la funcion muscular utilizando receptores del factor liberador de corticotropina.
CN100398551C (zh) 新的血管内皮细胞生长抑制剂同种型
ES2811060T3 (es) Anticuerpo contra péptido codificado por exón-21 de periostina y composición farmacéutica para prevenir o tratar enfermedades asociadas a inflamación que contienen el mismo
Hao et al. Vaccination with platelet-derived growth factor B kinoids inhibits CCl4-induced hepatic fibrosis in mice
JPH11341988A (ja) セマフォリンｋ１
JP2000506501A (ja) 抗イディオタイプ血管内皮細胞成長因子抗体およびそれらの医薬としての使用
US7527794B2 (en) Hybrid proteins with neuregulin heparin-binding domain for targeting to heparan sulfate proteoglycans
AU2002322762A1 (en) Hybrid proteins with neuregulin heparin-binding domain for targeting to heparan sulfate proteoglycans
JP4438987B2 (ja) 腫瘍学的目的のための体液中の骨シアロ蛋白（ｂｏｎｅｓｉａｌｏｐｒｏｔｅｉｎ）の測定方法
JP2005508870A6 (ja) 腫瘍学的目的のための体液中の骨シアロ蛋白（ｂｏｎｅｓｉａｌｏｐｒｏｔｅｉｎ）の測定方法
US6552177B2 (en) EH domain containing genes and proteins
US20130122028A1 (en) Novel vaccine that targets tumor vessels as an efficient tool in tumor therapy
JP2000159799A (ja) 副甲状腺ホルモンに対するヒトモノクローナル抗体
WO2026043932A1 (en) Constructs that selectively bind phosphatidylserine and their use in detecting and treating disease